Bayesian model averaging continual reassessment method in phase I clinical trials

Journal of the American Statistical Association

Volumn 104, Issue 487, 2009, Pages 954-968

  Yin, Guosheng ^a   Yuan, Ying ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adaptive design; Bayesian inference; Maximum tolerated dose; Model selection; Posterior model probability; Robustness; Toxicity probability

Indexed keywords

EID: 70349776681     PISSN: 01621459     EISSN: None     Source Type: Journal    
DOI: 10.1198/jasa.2009.ap08425     Document Type: Article

References (27)

1. Babb, J., Rogatko, A., and Zacks, S. (1998), "Cancer Phase I Clinical Trials: Efficient Dose Escalation With Overdose Control, " Statistics in Medicine, 17, 1103-1120. (Pubitemid 28221028)
2. Braun, T. M. (2002), "The Bivariate Continual Reassessment Method: Extending the CRM to Phase I Trials of Two Competing Outcomes, " Controlled Clinical Trials, 23, 240-256.
3. Durham, S. D., Flournoy, N., and Rosenberger, W. F. (1997), "A Random Walk Rule for Phase I Clinical Trials, " Biometrics, 53, 745-760.
4. Faries, D. (1994), "Practical Modification of the Continual ReassessmentMethods for Phase I Cancer Clinical Trials, " Journal of Biophamaceutical Statistics, 4, 147-164.
5. Garrett-Mayer, E. (2006), "The Continual Reassessment Method for Dose- Finding Studies: A Tutorial, " Clinical Trials, 3, 57-71.
6. Gasparini, M., and Eisele, J. (2000), "A Curve-FreeMethod for Phase I Clinical Trials, " Biometrics, 56, 609-615.
7. Goodman, S. N., Zahurak, M. L., and Piantadosi, S. (1995), "Some Practical Improvements in the Continual Reassessment Method for Phase I Studies, " Statistics in Medicine, 14, 1149-1161.
8. Heyd, J. M., and Carlin, P. B. (1999), "Adaptive Design Improvements in the Continual Reassessment Method for Phase I Studies, " Statistics in Medicine, 18, 1307-1321.
9. Hoeting, J. A., Madigan, D., Raftery, A. E., and Volinsky, C. T. (1999), "Bayesian Model Averaging: A Tutorial, " Statistical Science, 14, 382-401.
10. Ishizuka, N., and Ohashi, Y. (2001), "The Continual Reassessment Method and Its Applications: A Bayesian Methodology for Phase I Cancer Clinical Trials, " Statistics in Medicine, 20, 2661-2681.
11. Jakacki, R. I., Hamilton, M., Gilbertson, J. R., Blaney, S. M., Tersak, J., Krailo, M. D., Ingle, A. M., Voss, .
12. Leung, D. H.-Y., and Wang, Y.-G. (2002), "An Extension of the Continual ReassessmentMethod Using Decision Theory, " Statistics in Medicine, 21, 51- 63.
13. Madigan, D., and Raftery, A. E. (1994), "Model Selection and Accounting for Model Uncertainty in Graphical Models Using Occam's Window, " Journal of the American Statistical Association, 89, 1535-1546.
14. Mathew, P., Thall, P., Jones, D., Perez, C., Bucana, C., Troncoso, P., Kim, S., Fidler, I. J., and Logothetis, C. (2004), "Platelet-Derived Growth Factor Receptor Inhibitor Imatinib Mesylate and Docetaxel: A Modular Phase I Trial in Androgen-Independent Prostate Cancer, " Journal of Clinical Oncology, 22, 3323-3329. (Pubitemid 41103689)
15. Møller, S. (1995), "An Extension of the Continual Reassessment Methods Using a Preliminary Up-and-Down Design in a Dose Finding Study in Cancer Patients, in Order to Investigate a Greater Range of Doses, " Statistics in Medicine, 14, 911-922.
16. O'Quigley, J. (2002), Comment on "A Curve-Free Method for Phase I Clinical Trials, " by M. Gasparini and J. Eisele, Biometrics, 58, 245-249.
17. O'Quigley, J., and Chevret, S. (1991), "Methods for Dose Finding Studies in Cancer Clinical Trials: A Review and Results of a Monte Carlo Study, " Statistics in Medicine, 10, 1647-1664.
18. O'Quigley, J., and Shen, L. Z. (1996), "Continual Reassessment Method: A Likelihood Approach, " Biometrics, 52, 673-684.
19. O'Quigley, J., Pepe, M., and Fisher, L. (1990), "Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer, " Biometrics, 46, 33-48.
20. Piantadosi, S., Fisher, J., and Grossman, S. (1998), "Practical Implementation of a Modified Continual Reassessment Method for Dose Finding Trials, " Cancer Chemotherapy and Pharmacology, 41, 429-436.
21. Raftery, A. E., Madigan, D., and Hoeting, J. A. (1997), "Bayesian Model Averaging for Linear Regression Models, " Journal of the American Statistical Association, 92, 179-191.
22. Shen, L., and O'Quigley, J. (1996), "Consistency of Continual Reassessment Method Under Model Misspecification, " Biometrika, 83, 395-405.
23. Storer, B. E. (1989), "Design and Analysis of Phase I Clinical Trials," Biometrics, 45, 925-937.
24. Stylianou, M., and Flournoy, N. (2002), "Dose Finding Using the Biased Coin Up-and-Down Design and Isotonic Regression," Biometrics, 58, 171-177.
25. Ting, N. (2006), Dose Finding in Drug Development, Cambridge, MA: Springer.
26. Whitehead, J., and Brunier, H. (1995), "Bayesian Decision Procedures for Dose Determining Experiments, " Statistics in Medicine, 14, 885-893.
27. Yuan, Z., Chappell, R., and Bailey, H. (2007), "The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi-Likelihood Approach, " Biometrics, 63, 173-179.